Product
BS006
Aliases
BS006 Injection, oHSV2-PD-L1/CD3-BsAb
1 clinical trial
1 indication
Indication
Solid TumorClinical trial
A Phase 1, Open-label Study of BS006, an Oncolytic Virus, Administered by Intratumoral Injection in Patients With Advanced/Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2025-06-30